- Home
- EDRY vs ENLV Comparison
EDRY vs ENLV Comparison
Compare EDRY & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- ENLV
- Stock Information
- Founded
- EDRY 2018
- ENLV 2005
- Country
- EDRY Greece
- ENLV Israel
- Employees
- EDRY N/A
- ENLV N/A
- Industry
- EDRY Marine Transportation
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- ENLV Health Care
- Exchange
- EDRY Nasdaq
- ENLV Nasdaq
- Market Cap
- EDRY 27.3M
- ENLV 23.7M
- IPO Year
- EDRY N/A
- ENLV 1995
- Fundamental
- Price
- EDRY $10.26
- ENLV $1.25
- Analyst Decision
- EDRY
- ENLV Strong Buy
- Analyst Count
- EDRY 0
- ENLV 2
- Target Price
- EDRY N/A
- ENLV $10.00
- AVG Volume (30 Days)
- EDRY 1.3K
- ENLV 1.0M
- Earning Date
- EDRY 08-11-2025
- ENLV 08-29-2025
- Dividend Yield
- EDRY N/A
- ENLV N/A
- EPS Growth
- EDRY N/A
- ENLV N/A
- EPS
- EDRY N/A
- ENLV N/A
- Revenue
- EDRY $49,707,775.00
- ENLV N/A
- Revenue This Year
- EDRY N/A
- ENLV N/A
- Revenue Next Year
- EDRY $28.27
- ENLV N/A
- P/E Ratio
- EDRY N/A
- ENLV N/A
- Revenue Growth
- EDRY N/A
- ENLV N/A
- 52 Week Low
- EDRY $7.60
- ENLV $0.81
- 52 Week High
- EDRY $20.90
- ENLV $2.10
- Technical
- Relative Strength Index (RSI)
- EDRY 49.29
- ENLV 44.24
- Support Level
- EDRY $10.18
- ENLV $1.31
- Resistance Level
- EDRY $10.99
- ENLV $2.10
- Average True Range (ATR)
- EDRY 0.48
- ENLV 0.21
- MACD
- EDRY -0.07
- ENLV 0.00
- Stochastic Oscillator
- EDRY 17.45
- ENLV 3.41
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.